# US 2023/0065814 A1 · Conjugates of-electron-pair-donating heteroaromatic nitrogen-comprising compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065814 A1
- Document ID: US20230065814A1
- Status: Published application
- Kind: A1
- Application number: 17/596,831
- Filed: 2020-06-19
- Published: 2023-03-02
- Earliest claimed: 2019-06-21
- Assignees: Ascendis Pharma A/S
- Applicants: Ascendis Pharma A/S
- Inventors: Nicola BISEK; Samuel WEISBROD
- Web page: https://patentgrep.com/patent/US20230065814A1

## CPC

- A61K 47/6903: {the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel}
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6455: {Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids}
- A61P 35/00: Antineoplastic agents
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- Y02E 10/549: Organic PV cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02E: REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION

## Abstract

The present invention relates to conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising drugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said conjugates and the use of said conjugates as medicaments.

## Claims

### Claim 1

A conjugate or a pharmaceutically acceptable salt thereof comprising at least one moiety -D conjugated via at least one moiety -L1-L2- to at least one moiety Z, wherein a moiety -L1- is conjugated to a π-electron-pair-donating heteroaromatic N of a moiety -D and wherein the linkage between -D and -L1- is reversible and wherein a moiety -L2- is conjugated to Z, wherein
each -D is independently a π-electron-pair-donating heteroaromatic N-comprising moiety of a drug D-H;
each -L2- is independently a single bond or a spacer moiety;
each Z is independently a polymeric moiety or a C8-24 alkyl;
each -L1- is independently a linker moiety of formula (I):
wherein
the dashed line indicates the attachment to the π-electron-pair-donating heteroaromatic N of -D;
n is an integer selected from the group consisting of 0, 1, 2, 3 and 4;
═X1 is selected from the group consisting of ═O, ═S and ═N(R4);
—X2— is selected from the group consisting of —O—, —S—, —N(R5)— and —C(R6)(R6a)—;
—X3— is selected from the group consisting of
C(R10)(R10a)—, —C(R11)(R11a)—C(R12)(R12a)—, —O— and —C(O)—;
—R1, —R1a, —R6, —R6a, —R10, —R10a, —R11, —R11a, —R12, —R12a and each of —R2 and —R2a are independently selected from the group consisting of —H, —C(O)OH, halogen, —CN, —OH, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally substituted with one or more —R13, which are the same or different; and wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R14)—, —S(O)2N(R14)—, —S(O)N(R14)—, —S(O)2—, —S(O)—, —N(R14)S(O)2N(R14a)—, —S—, —N(R14), —OC(OR14)(R14a)—, —N(R14)C(O)N(R14a)— and —OC(O)N(R14)—;
—R3, —R4, —R5, —R7, —R8 and —R9 are independently selected from the group consisting of —H, -T, —CN, C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally substituted with one or more —R13, which are the same or different; and wherein C1-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, —C(O)O—, —O—, —C(O)—, —C(O)N(R14)—, —S(O)2N(R14)—, —S(O)N(R14)—, —S(O)2—, —S(O)—, —N(R14)S(O)2N(R14a)—, —S—, —N(R14)—, —OC(OR14)(R14a)—, —N(R14)C(O)N(R14a)— and —OC(O)N(R14)—;
each T is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicyclyl; wherein each T is independently optionally substituted with one or more —R13, which are the same or different;
wherein —R13 is selected from the group consisting of —H, —NO2, —OCH3, —CN, —N(R14)(R14a), —OH, —C(O)OH and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;
wherein —R14 and —R14a are independently selected from the group consisting of —H and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different;
optionally, one or more of the pairs —R1/—R1a, —R2/—R2a, two adjacent —R2, —R6/—R6a, —R10/—R10a, —R11/—R11a, —R12/—R12a and —R3/—R9 are joined together with the atom to which they are attached to form a C3-10 cycloalkyl, 3- to 10-membered heterocyclyl or an 8- to 11-membered heterobicyclyl;
optionally, one or more of the pairs —R1/—R2, —R1/—R5, —R1/—R6, —R1/—R9, —R1/—R10, —R2/—R5, —R3/—R6a, —R4/—R5, —R4/—R6, —R5/—R10, —R6/—R10 and —R11/—R12 are joined together with the atoms to which they are attached to form a ring -A-;
wherein -A- is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicyclyl;
optionally, —R1 and an adjacent —R2 form a carbon-carbon double bond provided that n is selected from the group consisting of 1, 2, 3 and 4;
optionally, two adjacent —R2 form a carbon-carbon double bond provided that n is selected from the group consisting of 2, 3 and 4;
provided that if —X2— is —N(R5)—, —X3— is selected from the group consisting of
and the distance between the nitrogen atom marked with an asterisk and the carbon atom marked with an asterisk in formula (I) is 5, 6 or 7 atoms and if present the carbon-carbon double bond formed between —R1 and —R2 or two adjacent —R2 is in a cis configuration; and
each -L1- is substituted with -L2- and optionally further substituted.

### Claim 2 (depends on 1)

The conjugate or pharmaceutically acceptable salt thereof of claim 1, wherein -D is selected from the group consisting of small molecule, medium size, peptide and protein drug moieties.

### Claim 3 (depends on 1, 2)

The conjugate or pharmaceutically acceptable salt thereof of claim 1 or 2, wherein -D is a small molecule drug moiety.

### Claim 4 (depends on 1, 2, 3)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 3, wherein Z is a polymeric moiety.

### Claim 5 (depends on 1, 2, 3, 4)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein Z is a water-insoluble polymeric moiety.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 5, wherein Z is a water-insoluble polymeric moiety comprising a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxypropyl methacrylates), poly(hydroxypropyloxazolines), poly(iminocarbonates), poly(lactic acids), poly(lactic-co-glycolic acids), poly(methacrylamides), poly(methacrylates), poly(methyloxazolines), poly(organophosphazenes), poly(ortho esters), poly(oxazolines), poly(propylene glycols), poly(siloxanes), poly(urethanes), poly(vinyl alcohols), poly(vinyl amines), poly(vinylmethylethers), poly(vinylpyrrolidones), silicones, celluloses, carbomethyl celluloses, hydroxypropyl methylcelluloses, chitins, chitosans, dextrans, dextrins, gelatins, hyaluronic acids and derivatives, functionalized hyaluronic acids, mannans, pectins, rhamnogalacturonans, starches, hydroxyalkyl starches, hydroxyethyl starches and other carbohydrate-based polymers, xylans, and copolymers thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 6, wherein Z is a hydrogel.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 7, wherein Z is a PEG-based or hyaluronic-acid based hydrogel.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 8, wherein Z is a PEG-based hydrogel.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 8, wherein Z is a hyaluronic-acid based hydrogel.

### Claim 11 (depends on 1, 2, 3, 4)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein Z is a water-soluble polymeric moiety.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 11, wherein ═X1 is ═O and —X2— is —O—.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 11, wherein ═X1 is ═O and —X2— is —N(R5)—.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 13, wherein -L2- is a spacer moiety.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 14, wherein -L2- has a molecular weight in the range of from 14 g/mol to 750 g/mol.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 15, wherein -L2- is a spacer moiety selected from the group consisting of -T′-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry1)—, —S(O)2N(Ry1)—, —S(O)N(Ry1)—, —S(O)2—, —S(O)—, —N(Ry1)S(O)2N(Ry1a)—, —S—, —N(Ry1)—, —OC(ORy1)(Ry1a)—, —N(Ry1)C(O)N(Ry1a)—, —OC(O)N(Ry1)—, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl; wherein -T′-, C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl are optionally substituted with one or more —Ry2, which are the same or different and wherein C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T′-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry3)—, —S(O)2N(Ry3)—, —S(O)N(Ry3)—, —S(O)2—, —S(O)—, —N(Ry3)S(O)2N(Ry3a)—, —S—, —N(Ry3)—, —OC(ORy3)(Ry3a)—, —N(Ry3)C(O)N(Ry3a)— and —OC(O)N(Ry3)—;
wherein —Ry1 and —Ry1a are independently selected from the group consisting of —H, -T′, C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl; wherein -T′, C1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more —Ry2, which are the same or different, and wherein C1-50 alkyl, C2-50 alkenyl and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T′-, —C(O)O—, —O—, —C(O)—, —C(O)N(Ry4)—, —S(O)2N(Ry4)—, —S(O)N(Ry4)—, —S(O)2—, —S(O)—, —N(Ry4)S(O)2N(Ry4a)—, —S—, —N(Ry4)—, —OC(ORy4)(Ry4a)—, —N(Ry4)C(O)N(Ry4a)—, and —OC(O)N(Ry4)—;
each T′ is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; wherein each T′ is independently optionally substituted with one or more —Ry2, which are the same or different;
each —Ry2 is independently selected from the group consisting of halogen, —CN, oxo (═O), —COORy5, —ORy5, —C(O)Ry5, —C(O)N(Ry5Ry5a), —S(O)2N(Ry5Ry5a), —S(O)N(Ry5Ry5a), —S(O)2Ry5, —S(O)Ry5, —N(Ry5)S(O)2N(Ry5aRy5b), —SRy5, —N(Ry5Ry5a), —NO2, —OC(O)Ry5, —N(Ry5)C(O)Ry5a, —N(Ry5)S(O)2Ry5a, —N(Ry5)S(O)Ry5a, —N(Ry5)C(O)ORy5a, —N(Ry5)C(O)N(Ry5aRy5b), —OC(O)N(Ry5Ry5a), and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different; and
each —Ry3, —Ry3a, —Ry4, —Ry4a, —Ry5, —Ry5a and —Ry5b is independently selected from the group consisting of —H and C1-6 alkyl; wherein C1-6 alkyl is optionally substituted with one or more halogen, which are the same or different.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 16, wherein one hydrogen given by —R3 is replaced by -L2-.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 17, wherein the linkage between Z and -L2- is stable.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 17, 18)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 11 and 13 to 18, wherein -L1- is of formula (Ix):
wherein the dashed line indicates the attachment to the π-electron-pair-donating heteroaromatic N of -D;
═X1, —R1, —R1a, —R2, —R2a, —R3, —R5 and n are used as defined in claim 1;
optionally, one or more of the pairs —R1/—R1a, —R2/—R2a, two adjacent —R2 are joined together with the atom to which they are attached to form a C3-10 cycloalkyl, 3- to 10-membered heterocyclyl or an 8- to 11-membered heterobicyclyl;
optionally, one or more of the pairs —R1/—R2, —R1/—R5, —R2/—R5 and —R4/—R5 are joined together with the atoms to which they are attached to form a ring -A-;
wherein -A- is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl and 8- to 11-membered heterobicyclyl;
optionally, —R1 and an adjacent —R2 form a carbon-carbon double bond provided that n is selected from the group consisting of 1, 2, 3 and 4;
optionally, two adjacent —R2 form a carbon-carbon double bond provided that n is selected from the group consisting of 2, 3 and 4;
and wherein the distance between the nitrogen atom marked with an asterisk and the carbon atom marked with an asterisk in formula (Ix) is 5, 6 or 7 atoms and if present the carbon-carbon double bond formed between —R1 and —R2 or two adjacent —R2 is in a cis configuration.

### Claim 20 (depends on 19)

The conjugate or pharmaceutically acceptable salt thereof of claim 19, wherein —R5 of formula (Ix) is methyl.

### Claim 21 (depends on 19, 20)

The conjugate or pharmaceutically acceptable salt thereof of claim 19 or 20, wherein —R1 and —R1a of formula (Ix) are both —H.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A pharmaceutical composition comprising the conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 21.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 21 or the pharmaceutical composition of claim 22 for use as a medicament.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The conjugate or pharmaceutically acceptable salt thereof of any one of claims 1 to 21 or the pharmaceutical composition of claim 22 for use in a method of treating a disease that can be treated with D-H.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method of preventing a disease or treating a patient suffering from a disease that can be prevented or treated with D-H, comprising administering an effective amount of the conjugate or the pharmaceutically acceptable salt thereof of any one of claims 1 to 21 or the pharmaceutical composition of claim 22 to the patient.
